Novel anticoagulants (NOACs) are the recent therapeutic breakthrough in the prophylaxis of
stroke in patients with nonvalvular atrial fibrillation (NVAF). Patients with NVAF seem to have …

Introduction Cardioembolic stroke, associated to nonvalvular atrial fibrillation (NVAF),
accounts for approximately one in every four strokes. Cardioembolic stroke has a bad …

Abstract Introduction New oral anticoagulants (NOACs) are approved for use in nonvalvular
atrial fibrillation (AF). Objectives This study aimed to evaluate the efficacy and safety of …

Objective To review all published clinical trials of NOACs in non-valvular AF assessing their
internal and external validity and to update all the relevant literature related to their efficacy …

OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is a common manifestation of cardiac
arrhythmia, whose significance is heightened in the context of an aging global population …

Background Warfarin, despite its known limitations, is the reference standard treatment for
patients with AF and risk factors for stroke. We performed a meta-analysis of phase III trials …

Background With the increasing use of novel oral anticoagulants (NOAC), patients are often
on both NOACs (apixaban, rivaroxaban and dabigatran) and antiplatelet therapy (aspirin or …

Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be
considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral …

Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia associated with an increased
risk of stroke. The role of anticoagulation therapy in the prevention of thrombosis and stroke …

Abstract Background New oral anticoagulants (NOACs) are effective and safe in patients
with nonvalvular atrial fibrillation (NVAF). Limited evidence is available regarding outcomes …